EcoDrugPlus

Matrix Metalloproteinase-14-Like

Ensembl ID : ENSOKIG00005043070
Gene Symbol: LOC109875099
3 Cross references
190 Possible Orthologues:

Matrix Metalloproteinase-9

Ensembl ID : ENSOKIG00005010179
Gene Symbol: LOC109908368
3 Cross references
209 Possible Orthologues:

Matrix Metalloproteinase-9-Like

Ensembl ID : ENSOKIG00005043531
Gene Symbol: LOC109884782
3 Cross references
209 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSOKIG00005030732
Gene Symbol: MTOR
3 Cross references
217 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSOKIG00005004859
Gene Symbol: MC1R
1 Cross references
155 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSOKIG00005024139
Gene Symbol: MC1R
3 Cross references
154 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOKIG00005046638
Gene Symbol: MC4R
1 Cross references
76 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOKIG00005026861
Gene Symbol: MC4R
1 Cross references
76 Possible Orthologues:

Melanocortin Receptor 3-Like

Ensembl ID : ENSOKIG00005013897
Gene Symbol: LOC109907043
3 Cross references
133 Possible Orthologues:

Melanocortin Receptor 4-Like

Ensembl ID : ENSOKIG00005026797
Gene Symbol: LOC109871547
3 Cross references
24 Possible Orthologues:

Melanocortin Receptor 4-Like

Ensembl ID : ENSOKIG00005024449
Gene Symbol: LOC109874696
3 Cross references
24 Possible Orthologues:

Melanoma Receptor Tyrosine-Protein Kinase

Ensembl ID : ENSOKIG00005006211
Gene Symbol: LOC109909822
2 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).